Literature DB >> 26934497

The PIM1 kinase promotes prostate cancer cell migration and adhesion via multiple signalling pathways.

Niina M Santio1, Maria Salmela2, Heidi Arola3, Sini K Eerola3, Jyrki Heino2, Eeva-Marja Rainio3, Päivi J Koskinen4.   

Abstract

The ability of cells to migrate and form metastases is one of the fatal hallmarks of cancer that can be conquered only with better understanding of the molecules and regulatory mechanisms involved. The oncogenic PIM kinases have been shown to support cancer cell survival and motility, but the PIM-regulated pathways stimulating cell migration and invasion are less well characterized than those affecting cell survival. Here we have identified the glycogen synthase kinase 3β (GSK3B) and the forkhead box P3 (FOXP3) transcription factor as direct PIM targets, whose tumour-suppressive effects in prostate cancer cells are inhibited by PIM-induced phosphorylation, resulting in increased cell migration. Targeting GSK3B is also essential for the observed PIM-enhanced expression of the prostaglandin-endoperoxide synthase 2 (PTGS2), which is an important regulator of both cell migration and adhesion. Accordingly, selective inhibition of PIM activity not only reduces cell migration, but also affects integrin-mediated cell adhesion. Taken together, these data provide novel mechanistic insights on how and why patients with metastatic prostate cancer may benefit from therapies targeting PIM kinases, and how such approaches may also be applicable to inflammatory conditions.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FoxP3; GSK3B; Integrins; PIM1; PTGS2; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26934497     DOI: 10.1016/j.yexcr.2016.02.018

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  18 in total

1.  Computational analysis of kinase inhibitor selectivity using structural knowledge.

Authors:  Yu-Chen Lo; Tianyun Liu; Kari M Morrissey; Satoko Kakiuchi-Kiyota; Adam R Johnson; Fabio Broccatelli; Yu Zhong; Amita Joshi; Russ B Altman
Journal:  Bioinformatics       Date:  2019-01-15       Impact factor: 6.937

Review 2.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

Review 4.  A systematic review on active sites and functions of PIM-1 protein.

Authors:  Youyi Zhao; Aziz Ur Rehman Aziz; Hangyu Zhang; Zhengyao Zhang; Na Li; Bo Liu
Journal:  Hum Cell       Date:  2022-01-09       Impact factor: 4.174

5.  PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.

Authors:  Mario Scarpa; Prerna Singh; Christopher M Bailey; Jonelle K Lee; Shivani Kapoor; Rena G Lapidus; Sandrine Niyongere; Jaya Sangodkar; Yin Wang; Danilo Perrotti; Goutham Narla; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2021-02-10       Impact factor: 6.009

6.  miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer.

Authors:  Omer Faruk Karatas; Jianghua Wang; Longjiang Shao; Mustafa Ozen; Yiqun Zhang; Chad J Creighton; Michael Ittmann
Journal:  Oncotarget       Date:  2017-07-24

7.  HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.

Authors:  Jiahui An; Jie Xu; Jiao Li; Song Jia; Xiaonan Li; Yanan Lu; Yuxin Yang; Zhuojia Lin; Xiaoru Xin; Mengying Wu; Qidi Zheng; Hu Pu; Xin Gui; Tianming Li; Dongdong Lu
Journal:  Oncotarget       Date:  2017-07-25

8.  Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells.

Authors:  Niina M Santio; Sebastian K-J Landor; Laura Vahtera; Jani Ylä-Pelto; Elina Paloniemi; Susumu Y Imanishi; Garry Corthals; Markku Varjosalo; Ganesh Babu Manoharan; Asko Uri; Urban Lendahl; Cecilia Sahlgren; Päivi J Koskinen
Journal:  Oncotarget       Date:  2016-07-12

9.  PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.

Authors:  Hui Cheng; Chongmei Huang; Xiaoqian Xu; Xiaoxia Hu; Shenglan Gong; Gusheng Tang; Xianmin Song; Weiping Zhang; Jianmin Wang; Li Chen; Jianmin Yang
Journal:  J Transl Med       Date:  2017-08-29       Impact factor: 5.531

10.  Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.

Authors:  Michael L Schulte; Allie Fu; Ping Zhao; Jun Li; Ling Geng; Shannon T Smith; Jumpei Kondo; Robert J Coffey; Marc O Johnson; Jeffrey C Rathmell; Joe T Sharick; Melissa C Skala; Jarrod A Smith; Jordan Berlin; M Kay Washington; Michael L Nickels; H Charles Manning
Journal:  Nat Med       Date:  2018-01-15       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.